.png)
MANKIND PHARMA LIMITED FILES DRHP WITH SEBI
Mankind Pharma Limited, India’s fourth largest pharmaceutical company in terms of Domestic Sales and second largest in terms of sales volume for FY22, has filed its Draft Red Herring Prospectus (“DRHP”) with market regulator Securities and Exchange Board of India (“SEBI”).
The Company’s initial public offering comprises an offer for sale of 40,058,884 equity shares of face value ₹ 1 each by selling shareholders including the promoters and existing investors.
The Company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
The offer for sale comprises of up to 3,705,443 equity shares by Ramesh Juneja, up to 3,505,149 equity shares by Rajeev Juneja, up to 2,804,119 equity shares by Sheetal Arora (“Collectively, The “Promoter Selling Shareholders”), up to 17,405,559 equity shares by Cairnhill CIPEF Limited, up to 2,623,863 equity shares by Cairnhill CGPE Limited, up to 9,964,711 equity shares by Beige Limited and up to 50,000 equity shares by Link Investment Trust (“Collectively, The “Investor Selling Shareholders”).
The Company is focused on the domestic market, as a result of which its revenue from operations in India contributed to 97.60% of its total revenue from operations for the Financial Year 2022, which was one of the highest among peers identified by IQVIA.
Kotak Mahindra Capital Company Limited, Axis Capital Limited, IIFL Securities Limited, Jefferies India Private Limited and J.P. Morgan India Private Limited are the Book Running Lead Managers to the issue.
Comments